Durable Response of Leptomeningeal Disease With Osimertinib and Pemetrexed in EGFR-Mutated Metastatic NSCLC: A Case Report

Durable Response of Leptomeningeal Disease With Osimertinib and Pemetrexed in EGFR-Mutated Metastatic NSCLC: A Case Report

Optimal management of EGFR-mutated NSCLC with leptomeningeal (LM) disease progression through EGFR tyrosine kinase inhibitor remains unclear. We present a 39-year-old man with EGFR-mutated NSCLC and LM disease progression through osimertinib 80 mg daily, with subsequent durable radiographic and symp...

Full description

Bibliographic Details
Main Authors: Cristina M. Merkhofer, MD, MHS, Christina S. Baik, MD, MPH
Format: Article
Language:English
Published: Elsevier 2021-06-01
Series:JTO Clinical and Research Reports
Subjects:
Pemetrexed
EGFR mutation
Non–small cell lung cancer
Leptomeningeal disease
Case report
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364321000369

Internet

http://www.sciencedirect.com/science/article/pii/S2666364321000369

Similar Items